AT252264B
(de)
|
1965-03-17 |
1967-02-10 |
Etapharm Chem Pharm Lab Ges M |
Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
|
US3393081A
(en)
*
|
1966-12-06 |
1968-07-16 |
Monsanto Co |
Heat sealable moisture barrier coatings for polystyrene articles
|
US3749776A
(en)
|
1970-08-28 |
1973-07-31 |
Allergan Pharma |
Method for blocking prostaglandin activity
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
SE390255B
(sv)
|
1974-02-18 |
1976-12-13 |
N G Y Torphammar |
Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
|
GB1478759A
(en)
|
1974-11-18 |
1977-07-06 |
Alza Corp |
Process for forming outlet passageways in pills using a laser
|
US3966749A
(en)
|
1975-02-10 |
1976-06-29 |
Interx Research Corporation |
Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
|
US4014335A
(en)
|
1975-04-21 |
1977-03-29 |
Alza Corporation |
Ocular drug delivery device
|
US4052505A
(en)
|
1975-05-30 |
1977-10-04 |
Alza Corporation |
Ocular therapeutic system manufactured from copolymer
|
US4144317A
(en)
|
1975-05-30 |
1979-03-13 |
Alza Corporation |
Device consisting of copolymer having acetoxy groups for delivering drugs
|
US4057619A
(en)
|
1975-06-30 |
1977-11-08 |
Alza Corporation |
Ocular therapeutic system with selected membranes for administering ophthalmic drug
|
US4063064A
(en)
|
1976-02-23 |
1977-12-13 |
Coherent Radiation |
Apparatus for tracking moving workpiece by a laser beam
|
US4186184A
(en)
|
1977-12-27 |
1980-01-29 |
Alza Corporation |
Selective administration of drug with ocular therapeutic system
|
US4190642A
(en)
|
1978-04-17 |
1980-02-26 |
Alza Corporation |
Ocular therapeutic system for dispensing a medication formulation
|
US4200098A
(en)
|
1978-10-23 |
1980-04-29 |
Alza Corporation |
Osmotic system with distribution zone for dispensing beneficial agent
|
US4285957A
(en)
|
1979-04-10 |
1981-08-25 |
Richardson-Merrell Inc. |
1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
|
US4303637A
(en)
|
1980-04-04 |
1981-12-01 |
Alza Corporation |
Medication indicated for ocular hypertension
|
US4281654A
(en)
|
1980-04-07 |
1981-08-04 |
Alza Corporation |
Drug delivery system for controlled ocular therapy
|
US4396625A
(en)
|
1980-05-13 |
1983-08-02 |
Sumitomo Chemical Company, Limited |
Treatment of glaucoma or ocular hypertension and ophthalmic composition
|
US4425346A
(en)
|
1980-08-01 |
1984-01-10 |
Smith And Nephew Associated Companies Limited |
Pharmaceutical compositions
|
US4304765A
(en)
|
1980-10-14 |
1981-12-08 |
Alza Corporation |
Ocular insert housing steroid in two different therapeutic forms
|
US4327725A
(en)
|
1980-11-25 |
1982-05-04 |
Alza Corporation |
Osmotic device with hydrogel driving member
|
JPS58126435U
(ja)
|
1982-02-19 |
1983-08-27 |
オリンパス光学工業株式会社 |
Ttlオ−トストロボ用絞り制御回路
|
US4454151A
(en)
|
1982-03-22 |
1984-06-12 |
Syntex (U.S.A.) Inc. |
Use of pyrrolo pyrroles in treatment of ophthalmic diseases
|
US4599353A
(en)
|
1982-05-03 |
1986-07-08 |
The Trustees Of Columbia University In The City Of New York |
Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
|
DE3220156C2
(de)
|
1982-05-28 |
1990-01-25 |
Heida Houston Tex. Thurlow |
Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
|
US4649151A
(en)
|
1982-09-27 |
1987-03-10 |
Health Research, Inc. |
Drugs comprising porphyrins
|
US5166331A
(en)
|
1983-10-10 |
1992-11-24 |
Fidia, S.P.A. |
Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
|
US4478818A
(en)
|
1982-12-27 |
1984-10-23 |
Alza Corporation |
Ocular preparation housing steroid in two different therapeutic forms
|
US4521210A
(en)
|
1982-12-27 |
1985-06-04 |
Wong Vernon G |
Eye implant for relieving glaucoma, and device and method for use therewith
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
US4675338A
(en)
|
1984-07-18 |
1987-06-23 |
Nippon Petrochemicals Co., Ltd. |
Tetrapyrrole therapeutic agents
|
US4693885A
(en)
|
1984-07-18 |
1987-09-15 |
Nippon Petrochemicals Co., Ltd. |
Tetrapyrrole therapeutic agents
|
FR2577509B1
(fr)
|
1985-02-21 |
1987-05-07 |
Nirvana Espar Systems Sa |
Mat de bateau a voile
|
US4656186A
(en)
|
1985-04-30 |
1987-04-07 |
Nippon Petrochemicals Co., Ltd. |
Tetrapyrrole therapeutic agents
|
US4668506A
(en)
|
1985-08-16 |
1987-05-26 |
Bausch & Lomb Incorporated |
Sustained-release formulation containing and amino acid polymer
|
FR2594438B1
(fr)
|
1986-02-14 |
1990-01-26 |
Labaz Sanofi Nv |
Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
|
US4959217A
(en)
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
CA1311686C
(en)
|
1986-06-25 |
1992-12-22 |
John Weldon Shell |
Controlled release bioerodible drug delivery system
|
US4863457A
(en)
|
1986-11-24 |
1989-09-05 |
Lee David A |
Drug delivery device
|
US5089509A
(en)
|
1988-09-15 |
1992-02-18 |
Allergan, Inc. |
Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
|
US4981871A
(en)
|
1987-05-15 |
1991-01-01 |
Abelson Mark B |
Treatment of ocular hypertension with class I calcium channel blocking agents
|
DE3734223A1
(de)
|
1987-10-09 |
1989-04-20 |
Boehringer Ingelheim Kg |
Implantierbares, biologisch abbaubares wirkstofffreigabesystem
|
US4853224A
(en)
|
1987-12-22 |
1989-08-01 |
Visionex |
Biodegradable ocular implants
|
US4997652A
(en)
|
1987-12-22 |
1991-03-05 |
Visionex |
Biodegradable ocular implants
|
US4865846A
(en)
|
1988-06-03 |
1989-09-12 |
Kaufman Herbert E |
Drug delivery system
|
US5190966A
(en)
|
1988-07-06 |
1993-03-02 |
Health Research, Inc. |
Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
|
US4968715A
(en)
|
1988-07-06 |
1990-11-06 |
Health Research, Inc. |
Use of purified hematoporphyrin trimers in photodynamic therapy
|
US5198460A
(en)
|
1988-07-20 |
1993-03-30 |
Health Research Inc. |
Pyropheophorbides and their use in photodynamic therapy
|
US5002962A
(en)
|
1988-07-20 |
1991-03-26 |
Health Research, Inc. |
Photosensitizing agents
|
US5093349A
(en)
|
1988-07-20 |
1992-03-03 |
Health Research Inc. |
Photosensitizing agents
|
ES2213504T1
(es)
|
1988-09-06 |
2004-09-01 |
Pfizer Health Ab |
Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
|
US4935498A
(en)
|
1989-03-06 |
1990-06-19 |
Board Of Regents, The University Of Texas System |
Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
US5173504A
(en)
|
1989-04-21 |
1992-12-22 |
Health Research, Inc. |
Bacteriochlorophyll-a derivatives useful in photodynamic therapy
|
US5171741A
(en)
|
1989-04-21 |
1992-12-15 |
Health Research, Inc. |
Bacteriochlorophyll-a derivatives useful in photodynamic therapy
|
US5019400A
(en)
|
1989-05-01 |
1991-05-28 |
Enzytech, Inc. |
Very low temperature casting of controlled release microspheres
|
US5034413A
(en)
|
1989-07-27 |
1991-07-23 |
Allergan, Inc. |
Intraocular pressure reducing 9,11-diacyl prostaglandins
|
US5028624A
(en)
|
1989-07-27 |
1991-07-02 |
Allergan, Inc. |
Intraocular pressure reducing 9,15-diacyl prostaglandins
|
US4932984A
(en)
|
1989-07-27 |
1990-06-12 |
The Dow Chemical Company |
Process for reduction of chlorinated solvent emissions
|
US5268178A
(en)
|
1989-09-25 |
1993-12-07 |
The Board Of Regents, The University Of Texas System |
Biodegradable antibiotic implants and methods of their use in treating and preventing infections
|
US5503721A
(en)
|
1991-07-18 |
1996-04-02 |
Hri Research, Inc. |
Method for photoactivation
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
US5075115A
(en)
|
1990-04-02 |
1991-12-24 |
Fmc Corporation |
Process for polymerizing poly(lactic acid)
|
US5232844A
(en)
|
1990-05-15 |
1993-08-03 |
New York Blood Center |
Photodynamic inactivation of viruses in cell-containing compositions
|
US5196460A
(en)
*
|
1990-05-29 |
1993-03-23 |
Repap Technologies Inc. |
Rubber compositions containing high purity lignin derivatives
|
US5100431A
(en)
|
1990-09-27 |
1992-03-31 |
Allergan, Inc. |
Single stitch suture needle and method
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
CA2055522A1
(en)
|
1990-12-12 |
1992-06-13 |
Masako Andoh |
Microspheres for ophthalmic use
|
US5378475A
(en)
|
1991-02-21 |
1995-01-03 |
University Of Kentucky Research Foundation |
Sustained release drug delivery devices
|
JP3351525B2
(ja)
|
1991-06-21 |
2002-11-25 |
ジェネティックス・インスティテュート・インコーポレイテッド |
骨形成性蛋白医薬処方物
|
US5356629A
(en)
|
1991-07-12 |
1994-10-18 |
United States Surgical Corporation |
Composition for effecting bone repair
|
US5169638A
(en)
|
1991-10-23 |
1992-12-08 |
E. R. Squibb & Sons, Inc. |
Buoyant controlled release powder formulation
|
US5543154A
(en)
|
1991-12-27 |
1996-08-06 |
Merck & Co., Inc. |
Controlled release nifedipine delivery device
|
US5656297A
(en)
|
1992-03-12 |
1997-08-12 |
Alkermes Controlled Therapeutics, Incorporated |
Modulated release from biocompatible polymers
|
US5384333A
(en)
|
1992-03-17 |
1995-01-24 |
University Of Miami |
Biodegradable injectable drug delivery polymer
|
IT1263116B
(it)
|
1992-04-09 |
1996-07-30 |
Rotta Research Lab |
Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
|
US5655832A
(en)
|
1992-04-16 |
1997-08-12 |
Tir Technologies, Inc. |
Multiple wavelength light processor
|
US5244914A
(en)
|
1992-04-27 |
1993-09-14 |
American Cyanamid Company |
Stable porfimer sodium compositions and methods for their manufacture
|
US5178635A
(en)
|
1992-05-04 |
1993-01-12 |
Allergan, Inc. |
Method for determining amount of medication in an implantable device
|
US6217869B1
(en)
|
1992-06-09 |
2001-04-17 |
Neorx Corporation |
Pretargeting methods and compounds
|
US5972991A
(en)
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5688819A
(en)
|
1992-09-21 |
1997-11-18 |
Allergan |
Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5922773A
(en)
|
1992-12-04 |
1999-07-13 |
The Children's Medical Center Corp. |
Glaucoma treatment
|
US5707643A
(en)
|
1993-02-26 |
1998-01-13 |
Santen Pharmaceutical Co., Ltd. |
Biodegradable scleral plug
|
US5994341A
(en)
|
1993-07-19 |
1999-11-30 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic Compositions and methods for the treatment of arthritis
|
WO1995003807A1
(en)
|
1993-07-27 |
1995-02-09 |
The University Of Sydney |
Treatment of age-related macular degeneration
|
US5504074A
(en)
|
1993-08-06 |
1996-04-02 |
Children's Medical Center Corporation |
Estrogenic compounds as anti-angiogenic agents
|
US5385887A
(en)
|
1993-09-10 |
1995-01-31 |
Genetics Institute, Inc. |
Formulations for delivery of osteogenic proteins
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
US6051576A
(en)
|
1994-01-28 |
2000-04-18 |
University Of Kentucky Research Foundation |
Means to achieve sustained release of synergistic drugs by conjugation
|
DE4403326C1
(de)
|
1994-02-03 |
1995-06-22 |
Hans Reinhard Prof Dr Koch |
Intraokulare Linsenanordnung zur Astigmatismuskorrektur
|
US5798349A
(en)
|
1994-03-14 |
1998-08-25 |
The General Hospital Corporation |
Use of green porphyrins to treat neovasculature in the eye
|
US5516522A
(en)
|
1994-03-14 |
1996-05-14 |
Board Of Supervisors Of Louisiana State University |
Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
|
US5466233A
(en)
|
1994-04-25 |
1995-11-14 |
Escalon Ophthalmics, Inc. |
Tack for intraocular drug delivery and method for inserting and removing same
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US6270492B1
(en)
|
1994-09-09 |
2001-08-07 |
Cardiofocus, Inc. |
Phototherapeutic apparatus with diffusive tip assembly
|
US5585401A
(en)
|
1994-12-09 |
1996-12-17 |
The Reents Of The University Of California |
Method for enhancing outflow of aqueous humor in treatment of glaucoma
|
US5972326A
(en)
|
1995-04-18 |
1999-10-26 |
Galin; Miles A. |
Controlled release of pharmaceuticals in the anterior chamber of the eye
|
US5612027A
(en)
|
1995-04-18 |
1997-03-18 |
Galin; Miles A. |
Controlled release of miotic and mydriatic drugs in the anterior chamber
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US6369116B1
(en)
|
1995-06-02 |
2002-04-09 |
Oculex Pharmaceuticals, Inc. |
Composition and method for treating glaucoma
|
HUP9700322A3
(en)
|
1995-06-09 |
2001-03-28 |
Euro Celtique Sa |
Formulations and methods for providing prolonged local anesthesia
|
US5906920A
(en)
|
1995-08-29 |
1999-05-25 |
The Salk Institute For Biological Studies |
Methods for the detection of ligands for retinoid X receptors
|
US5958954A
(en)
|
1995-09-01 |
1999-09-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
US5776699A
(en)
|
1995-09-01 |
1998-07-07 |
Allergan, Inc. |
Method of identifying negative hormone and/or antagonist activities
|
US5877207A
(en)
|
1996-03-11 |
1999-03-02 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
US6066675A
(en)
|
1996-09-13 |
2000-05-23 |
The Regents Of The University Of California |
Method for treatment of retinal diseases
|
US5913884A
(en)
|
1996-09-19 |
1999-06-22 |
The General Hospital Corporation |
Inhibition of fibrosis by photodynamic therapy
|
US6270749B1
(en)
|
1996-12-11 |
2001-08-07 |
Pharmacyclics, Inc. |
Use of Texaphyrin in ocular diagnosis and therapy
|
US6274614B1
(en)
|
1997-02-11 |
2001-08-14 |
Qlt Inc. |
Methods, compositions and articles for reducing or preventing the effects of inflammation
|
US5919970A
(en)
|
1997-04-24 |
1999-07-06 |
Allergan Sales, Inc. |
Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
|
EP0994709A4
(en)
|
1997-06-30 |
2006-02-01 |
Allergan Inc |
CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY
|
CA2300154C
(en)
|
1997-08-11 |
2008-07-08 |
Allergan Sales, Inc. |
Sterile bioerodible implant device with improved biocompatability and method
|
US6306426B1
(en)
|
1997-08-11 |
2001-10-23 |
Allergan Sales, Inc. |
Implant device with a retinoid for improved biocompatibility
|
FR2767699A1
(fr)
*
|
1997-08-28 |
1999-02-26 |
Oreal |
Composition filmogene epaissie
|
US6207713B1
(en)
*
|
1997-09-17 |
2001-03-27 |
Eric T. Fossel |
Topical and oral delivery of arginine to cause beneficial effects
|
US6646001B2
(en)
|
1997-12-19 |
2003-11-11 |
Alcon Manufacturing, Ltd. |
Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
|
US6271220B1
(en)
|
1998-03-11 |
2001-08-07 |
Allergan Sales, Inc. |
Anti-angiogenic agents
|
DE69940738D1
(de)
|
1998-07-09 |
2009-05-28 |
Curelight Medical Ltd |
Vorrichtung und verfahren zur wirkungsvollen hochenergetischen photodynamischen therapie von akne vulgaris und seborrhoe
|
EP1131114B1
(en)
|
1998-11-20 |
2004-06-16 |
The University of Connecticut |
Apparatus and method for control of tissue/implant interactions
|
US6217895B1
(en)
|
1999-03-22 |
2001-04-17 |
Control Delivery Systems |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
US6482854B1
(en)
|
1999-03-25 |
2002-11-19 |
Massachusetts Eye And Ear Infirmary |
Glaucoma treatment
|
US6290713B1
(en)
|
1999-08-24 |
2001-09-18 |
Thomas A. Russell |
Flexible illuminators for phototherapy
|
US6317616B1
(en)
|
1999-09-15 |
2001-11-13 |
Neil David Glossop |
Method and system to facilitate image guided surgery
|
AU768400B2
(en)
|
1999-10-21 |
2003-12-11 |
Alcon Inc. |
Drug delivery device
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US6728918B1
(en)
|
1999-11-01 |
2004-04-27 |
Matsushita Electric Industrial Co., Ltd. |
Relay transmission method and system, and device used thereof
|
US6319273B1
(en)
|
1999-12-16 |
2001-11-20 |
Light Sciences Corporation |
Illuminating device for treating eye disease
|
US6395787B1
(en)
|
2000-02-08 |
2002-05-28 |
Allergan Sales, Inc. |
Ocular hypotensive lipids
|
CA2398901C
(en)
|
2000-02-10 |
2010-11-16 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
US7708711B2
(en)
|
2000-04-14 |
2010-05-04 |
Glaukos Corporation |
Ocular implant with therapeutic agents and methods thereof
|
US20040208910A1
(en)
|
2000-04-26 |
2004-10-21 |
Control Delivery Systems, Inc. |
Sustained release device and method for ocular delivery of adrenergic agents
|
PE20020146A1
(es)
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
HUP0303197A3
(en)
|
2000-07-14 |
2008-03-28 |
Allergan Inc |
Compositions containing alpha-2 adrenergic agonist components
|
US6357568B1
(en)
|
2000-09-27 |
2002-03-19 |
Shou Mao Chen |
Structure for protecting a luggage shell
|
AU2002248284A1
(en)
|
2000-11-01 |
2002-08-06 |
Allergan, Inc. |
Compositions for treatment of ocular neovascularization
|
AU3649502A
(en)
|
2000-11-29 |
2002-06-11 |
Oculex Pharm Inc |
Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
|
US6595945B2
(en)
|
2001-01-09 |
2003-07-22 |
J. David Brown |
Glaucoma treatment device and method
|
US6713081B2
(en)
|
2001-03-15 |
2004-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Ocular therapeutic agent delivery devices and methods for making and using such devices
|
EP1387671A1
(en)
|
2001-05-03 |
2004-02-11 |
MASSACHUSETTS EYE & EAR INFIRMARY |
Implantable drug delivery device and use thereof
|
TWI298257B
(en)
|
2001-05-31 |
2008-07-01 |
Allergan Inc |
Hypotensive lipid and timolol compositions and methods of using same
|
US6713268B2
(en)
|
2001-06-26 |
2004-03-30 |
Allergan, Inc. |
Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
|
US20030220376A1
(en)
|
2001-08-10 |
2003-11-27 |
Pharmacia Corporation |
Methods for treating carbonic anhydrase mediated disorders
|
US7749528B2
(en)
|
2001-08-29 |
2010-07-06 |
Ricardo Azevedo Pontes De Carvalho |
Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
AU2002341881B2
(en)
|
2001-09-27 |
2008-05-08 |
Allergan, Inc. |
3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
US20040058313A1
(en)
|
2002-04-24 |
2004-03-25 |
Abreu Marcio Marc |
Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
|
AU2003217531A1
(en)
|
2002-05-02 |
2003-11-17 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
US20050245509A1
(en)
|
2002-08-29 |
2005-11-03 |
Santen Pharmacecutical Co., Ltd. |
Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
|
KR20050047118A
(ko)
*
|
2002-09-18 |
2005-05-19 |
알러간, 인코포레이티드 |
안과 임플란트의 수송을 위한 방법 및 장치
|
US6899717B2
(en)
|
2002-09-18 |
2005-05-31 |
Allergan, Inc. |
Methods and apparatus for delivery of ocular implants
|
AU2003295409B2
(en)
|
2002-11-06 |
2010-02-11 |
Durect Corporation |
Controlled release depot formulations
|
JP2004196787A
(ja)
|
2002-12-04 |
2004-07-15 |
Santen Pharmaceut Co Ltd |
結膜下デポによるドラッグデリバリーシステム
|
US20040137059A1
(en)
|
2003-01-09 |
2004-07-15 |
Thierry Nivaggioli |
Biodegradable ocular implant
|
US20090148527A1
(en)
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
US7186744B2
(en)
|
2003-11-13 |
2007-03-06 |
Allergan, Inc. |
Prostamides for the treatment of glaucoma and related diseases
|
JP2007520496A
(ja)
|
2004-02-04 |
2007-07-26 |
レットメッド ピーティーワイ リミテッド |
徐放性ステロイド組成物
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US20060182781A1
(en)
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US20050244462A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US20050244458A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US20050244461A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244478A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244465A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244466A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20050244471A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US7091231B2
(en)
|
2004-12-10 |
2006-08-15 |
Allergan, Inc. |
12-Aryl prostaglandin analogs
|
PL1856042T3
(pl)
|
2005-03-10 |
2012-11-30 |
Allergan Inc |
Podstawione gamma laktamy jako środki terapeutyczne
|
US7585895B2
(en)
|
2005-12-06 |
2009-09-08 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
US7427685B2
(en)
|
2005-12-06 |
2008-09-23 |
Allergan, Inc. |
Therapeutic substituted cyclopentanes
|
CN101330914A
(zh)
|
2005-12-16 |
2008-12-24 |
爱尔康公司 |
使用alk5调节剂控制眼内压
|
ES2653845T3
(es)
|
2006-01-17 |
2018-02-09 |
Novartis Ag |
Dispositivo de tratamiento de administración de fármaco
|
AU2007212271B2
(en)
*
|
2006-02-09 |
2012-11-01 |
Santen Pharmaceutical Co., Ltd. |
Stable formulations, and methods of their preparation and use
|
US7592364B2
(en)
|
2006-02-28 |
2009-09-22 |
Allergan, Inc. |
Substituted gamma lactams as therapeutic agents
|
US9039761B2
(en)
|
2006-08-04 |
2015-05-26 |
Allergan, Inc. |
Ocular implant delivery assemblies with distal caps
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US8846073B2
(en)
*
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
US7589213B2
(en)
|
2007-04-27 |
2009-09-15 |
Old David W |
Therapeutic substituted lactams
|
US8231892B2
(en)
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
US7947732B2
(en)
|
2007-07-13 |
2011-05-24 |
Allergan, Inc. |
Therapeutic substituted chlorocyclopentanols
|
US7740604B2
(en)
|
2007-09-24 |
2010-06-22 |
Ivantis, Inc. |
Ocular implants for placement in schlemm's canal
|
IL186598A0
(en)
|
2007-10-11 |
2008-11-03 |
Mohammad Abdulrazik |
Composition and method for the treatment or prevention of glaucoma and ocular hypertension
|
CN102977048A
(zh)
|
2007-11-09 |
2013-03-20 |
阿勒根公司 |
具有前列腺素活性的取代环戊烷
|
PL2291368T3
(pl)
|
2008-04-24 |
2013-05-31 |
Allergan Inc |
Podstawione gama laktamy jako środki terapeutyczne
|
EP2296621A1
(en)
|
2008-05-20 |
2011-03-23 |
Yale University |
Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
|
US20100098772A1
(en)
|
2008-10-21 |
2010-04-22 |
Allergan, Inc. |
Drug delivery systems and methods for treating neovascularization
|
US20100104654A1
(en)
|
2008-10-27 |
2010-04-29 |
Allergan, Inc. |
Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
WO2010093945A2
(en)
*
|
2009-02-13 |
2010-08-19 |
Glaukos Corporation |
Uveoscleral drug delivery implant and methods for implanting the same
|
US20100247606A1
(en)
*
|
2009-03-25 |
2010-09-30 |
Allergan, Inc. |
Intraocular sustained release drug delivery systems and methods for treating ocular conditions
|
KR20180117211A
(ko)
|
2010-01-22 |
2018-10-26 |
알러간, 인코포레이티드 |
전방내 서방성 치료제 이식물
|
US20130071349A1
(en)
|
2010-03-02 |
2013-03-21 |
Allergan, Inc. |
Biodegradable polymers for lowering intraocular pressure
|